

May 12, 2025

| | |
|--|--|
| To The Manager, Listing Department National Stock Exchange of India Ltd. Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: BLISSGVS | To The General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 506197 |
|--|--|

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on Monday, May 12, 2025

We would like to inform you that, the Board Meeting of the Company was held today i.e. on Monday, May 12, 2025 at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the following matters amongst others: -

1. The Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2025 along with the audit report of the auditors. The copy of the said financial and Audit Reports are enclosed herewith as '**Annexure-1**'.
2. Declaration of unmodified opinion for annual audited standalone and consolidated financial results for the year ended March 31, 2025 in accordance with Regulation 33(3)(d) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016 is enclosed herewith as '**Annexure - 2**';
3. Pursuant to SEBI circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, we are submitting herewith the Integrated Filing (Financial) for the quarter ended March 31, 2025 as '**Annexure - 3**'.
4. Recommended Final dividend of 50% i.e. 0.50 paisa per equity share on face value of Rs.1/- each for the financial year ended March 31, 2025, subject to approval of the shareholders in the forthcoming 40th Annual General Meeting of the Company ('**40th AGM**');
5. Re-appointment of M/s. BDO India LLP, a Chartered Accountant having LLP registration no. AAB-7880 as Internal Auditor of the Company for the financial year 2025-26. The brief profile of the internal auditor is enclosed herewith as '**Annexure - 4**';
6. Appointment of M/s. AVS & Associates, Practicing Company Secretaries, Peer Reviewed Firm as Secretarial Auditors of the Company for the audit period of five consecutive years commencing from F.Y. 2025-26 till F.Y. 2029-2030, subject to approval of the shareholders of the Company at the ensuing 40th AGM. The brief profile of the Secretarial auditor is enclosed herewith as '**Annexure - 5**';

7. **Sale/Disposal of Step-down Subsidiary by the Wholly Owned Subsidiary of the Company:**

Bliss GVS International Pte. Ltd., a wholly owned subsidiary of Bliss GVS Pharma Limited, has transferred its entire holding of 51% equity shares in Greenlife Bliss Healthcare Limited to Greenlife Pharmaceuticals Limited. Pursuant to this disposal, Greenlife Bliss Healthcare Limited has ceased to be a subsidiary of Bliss GVS International Pte. Ltd. and, accordingly, also ceases to be a step-down subsidiary of Bliss GVS Pharma Limited. The detailed disclosure in this regard is enclosed herewith as '**Annexure - 6**'.

8. Subject to shareholders and other statutory and regulatory approvals, as applicable, Issuance and allotment of upto 8,50,000 Equity Shares for non-cash consideration as Sweat Equity Shares to Mr. Gagan Harsh Sharma, Managing Director of the Company in accordance with the provisions of Chapter IV of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The requisite details are enclosed herewith as "**Annexure - 7**".

9. Subject to shareholders and other statutory and regulatory approvals, as applicable, Issuance and allotment of upto 3,60,000 Equity Shares for non-cash consideration as Sweat Equity Shares to Mr. Vishal Vijay Rao, Vice-President of the Company in accordance with the provisions of Chapter IV of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The requisite details are enclosed herewith as "**Annexure - 7**".

10. 40th Annual General Meeting ("**40th AGM or AGM**") of the Company for the financial year ended March 31, 2025 has been scheduled to be held on Thursday, July 31, 2025 at 11:30 A.M. through Video Conferencing ('VC')/Other Audio Visual Means ('OAVM') facility pursuant to the Circular No.14 / 2020 dated April 8, 2020, Circular No. 17 / 2020 dated April 13, 2020 and Circular No. 20 / 2020 dated May 5, 2020 and all other related subsequent circulars issued in this regard and latest one being General Circular No. 09/2024 dated September 19, 2024, issued by the Ministry of Corporate Affairs ("**MCA Circulars**") which does not require physical presence of members at a common venue. The deemed venue for the 40th AGM shall be the registered office of the Company.

The Board of Directors meeting commenced at 03:56 PM and concluded at 06:30 PM.

Kindly take the above information on your record and acknowledge it.

Thanking you.

Yours faithfully,

For **Bliss GVS Pharma Limited**

Deepak Sawant
Chief Financial Officer

Encl: As above

BLISS GVS PHARMA LIMITED
Regd. Office - 102, Hyde Park, Sakinaka Road, Andheri East- Mumbai-400072
CIN - L24230MH1984PLC034771
Statement of Audited Standalone and Consolidated Financial Results for the Quarter and Year ended March 31, 2025

(₹ In Lakh)

| Sr. No. | Particulars | Standalone | | | | | Consolidated | | | | |
|---------|--|----------------------------|--------------|----------------------------|--------------|------------|----------------------------|--------------|----------------------------|--------------|--------------|
| | | Quarter Ended | | Year Ended | | Year Ended | Quarter Ended | | Year Ended | | Year Ended |
| | | Mar 31, 2025 | Dec 31, 2024 | Mar 31, 2024 | Mar 31, 2025 | | Mar 31, 2025 | Dec 31, 2024 | Mar 31, 2024 | Mar 31, 2025 | Mar 31, 2024 |
| | | Audited (Refer Note 12) | Un-Audited | Audited (Refer Note 12) | Audited | Audited | Audited (Refer Note 12) | Un-Audited | Audited (Refer Note 12) | Audited | Audited |
| I | Revenue from Operations | 15,600.24 | 17,959.37 | 16,381.74 | 66,720.46 | 60,545.97 | 19,798.58 | 21,041.82 | 19,812.83 | 80,972.62 | 77,024.49 |
| II | Other Income | 936.08 | 1,166.06 | 846.38 | 3,621.65 | 3,350.05 | 1,206.85 | 1,526.51 | 559.95 | 3,649.35 | 2,873.74 |
| III | Total Income (I+II) | 16,536.32 | 19,125.43 | 17,228.12 | 70,342.11 | 63,896.02 | 21,005.43 | 22,568.33 | 20,372.78 | 84,621.97 | 79,898.23 |
| IV | Expenses | | | | | | | | | | |
| a. | Cost of Materials consumed | 6,878.59 | 8,817.99 | 7,849.76 | 33,947.44 | 30,582.77 | 7,661.21 | 9,741.03 | 8,727.87 | 37,251.39 | 33,911.63 |
| b. | Purchase of Stock-in-Trade | - | - | - | - | - | 1,352.97 | 1,903.16 | 798.26 | 4,928.50 | 5,134.60 |
| c. | Changes in inventories of work in process, finished goods and stock in trade | 918.83 | 803.86 | -87.34 | 663.23 | (536.18) | 928.63 | (224.68) | 20.65 | (811.07) | (834.66) |
| d. | Employee Benefits Expenses | 2,522.46 | 2,629.89 | 2,088.33 | 9,941.78 | 8,259.15 | 2,824.38 | 2,976.12 | 2,451.23 | 11,205.04 | 9,558.44 |
| e. | Finance Costs | 129.98 | 66.83 | 153.10 | 658.38 | 580.61 | 167.79 | 108.47 | 185.31 | 812.00 | 691.21 |
| f. | Depreciation and Amortisation Expenses | 743.45 | 695.70 | 622.92 | 2,704.72 | 2,351.93 | 803.61 | 755.07 | 684.66 | 2,941.76 | 2,637.98 |
| g. | Other Expenses | 3,907.34 | 3,134.15 | 3,841.38 | 13,009.45 | 11,623.36 | 4,922.79 | 3,667.27 | 4,980.05 | 15,730.43 | 14,192.22 |
| | Total Expenses | 15,100.65 | 16,148.42 | 14,642.83 | 60,925.00 | 52,761.64 | 18,661.38 | 18,926.44 | 17,848.03 | 72,058.05 | 65,291.42 |
| V | Profit before exceptional Items and tax (III-IV) | 1,435.67 | 2,977.01 | 2,585.29 | 9,417.11 | 11,134.38 | 2,344.05 | 3,641.89 | 2,524.75 | 12,563.92 | 14,606.81 |
| VI | Exceptional Items | - | - | (4,108.61) | - | (4,108.61) | - | - | (2,919.61) | - | (2,919.61) |
| VII | Profit/ (Loss) before Tax (V-VI) | 1,435.67 | 2,977.01 | (1,523.32) | 9,417.11 | 7,025.77 | 2,344.05 | 3,641.89 | (394.86) | 12,563.92 | 11,687.20 |
| VIII | Tax Expenses | | | | | | | | | | |
| i. | Current Tax | 467.92 | 1,027.09 | 598.98 | 3,073.77 | 2,633.54 | 662.57 | 1,375.67 | 843.14 | 4,012.73 | 3,240.10 |
| ii. | Deferred Tax | (104.43) | (155.33) | (976.22) | (478.90) | (754.92) | 89.26 | (314.12) | (746.91) | (399.18) | 203.33 |
| iii. | Short/ (Excess) Provision of earlier years | (73.03) | - | - | (74.63) | 82.66 | (73.04) | - | 0.26 | (75.16) | 85.98 |
| IX | Net Profit/ (Loss) for the period (VII-VIII) | 1,145.21 | 2,105.25 | (1,146.08) | 6,896.87 | 5,064.49 | 1,665.26 | 2,580.34 | (491.35) | 9,025.53 | 8,157.79 |
| X | Other Comprehensive Income | | | | | | | | | | |
| i. | Items that will not be reclassified to profit or loss | | | | | | | | | | |
| (i) | Remeasurement of the defined benefit liabilities/ (assets) | (19.07) | (15.48) | 0.71 | (74.45) | (20.53) | (20.57) | (15.48) | (1.83) | (75.95) | (23.07) |
| (ii) | Income tax on remeasurement of defined benefits liabilities/ (assets) | 4.79 | 3.90 | (0.18) | 18.73 | 5.17 | 5.17 | 3.90 | 0.46 | 19.11 | 5.81 |
| ii. | Items that will be reclassified to profit or loss | | | | | | | | | | |
| (i) | Exchange differences in translating the financial statements of foreign operations | - | - | - | - | - | (45.15) | 2.91 | 2,403.20 | (237.99) | 780.77 |
| (ii) | Income tax relating to items that will be reclassified to profit or loss | - | - | - | - | - | 11.73 | (0.73) | (649.55) | 60.27 | (308.66) |
| XI | Total Comprehensive Income/ (Loss) for the period | 1,130.93 | 2,093.67 | (1,145.55) | 6,841.15 | 5,049.13 | 1,616.44 | 2,570.94 | 1,260.93 | 8,790.97 | 8,612.64 |
| XII | Profit attributable to: | | | | | | | | | | |
| i. | Owners of the Company | - | - | - | - | - | 1,553.91 | 2,380.24 | (914.77) | 8,429.93 | 7,545.41 |
| ii. | Non-controlling Interests | - | - | - | - | - | 111.35 | 200.10 | 423.42 | 595.60 | 612.38 |
| XIII | Other Comprehensive Income/ (Loss) attributable to: | | | | | | | | | | |
| i. | Owners of the Company | - | - | - | - | - | (51.63) | (32.68) | 1,839.79 | (212.44) | 673.71 |
| ii. | Non-controlling Interests | - | - | - | - | - | 2.81 | 23.28 | (87.51) | (22.12) | (218.86) |
| XIV | Total Comprehensive Income/ (Loss) attributable to: | | | | | | | | | | |
| i. | Owners of the Company | - | - | - | - | - | 1,502.28 | 2,347.56 | 1,925.02 | 8,217.49 | 8,219.12 |
| ii. | Non-controlling Interests | - | - | - | - | - | 114.16 | 223.38 | 335.91 | 573.48 | 393.52 |
| XV | Paid up equity share capital (Face Value - ₹ 1/- each) | 1,053.70 | 1,053.66 | 1,046.91 | 1,053.70 | 1,046.91 | 1,053.70 | 1,053.66 | 1,046.91 | 1,053.70 | 1,046.91 |
| XVI | Other Equity | - | - | - | 1,04,803.61 | 97,797.47 | - | - | - | 1,03,983.86 | 95,672.42 |
| XVII | Earnings Per Share Basic & Diluted (Not Annualised) (₹) | | | | | | | | | | |
| i. | Basic | 1.08 | 2.00 | (1.11) | 6.56 | 4.85 | 1.47 | 2.27 | (0.88) | 8.02 | 7.23 |
| ii. | Diluted | 1.07 | 2.00 | (1.08) | 6.50 | 4.77 | 1.46 | 2.27 | (0.86) | 7.95 | 7.11 |





BLISS GVS PHARMA LIMITED

Regd. Office - 102, Hyde Park, Sakinaka Road, Andheri East- Mumbai-400072

CIN - L24230MH1984PLC034771

Balance Sheet as at March 31, 2025

(₹ in Lakh)

| Particulars | Standalone | | Consolidated | |
|--|--------------------|--------------------|--------------------|--------------------|
| | March 31, 2025 | March 31, 2024 | March 31, 2025 | March 31, 2024 |
| | Audited | Audited | Audited | Audited |
| ASSETS | | | | |
| NON-CURRENT ASSETS | | | | |
| (a) Property, Plant and Equipment (Includes ROU) | 36,766.47 | 32,985.73 | 39,700.72 | 36,155.19 |
| (b) Capital Work-in-Progress | 2,058.18 | 782.70 | 2,071.10 | 782.70 |
| (c) Investment Property | 68.29 | 68.45 | 68.29 | 68.45 |
| (d) Goodwill | - | - | 771.11 | 771.11 |
| (e) Other Intangible Assets | 22.06 | 9.65 | 23.03 | 10.67 |
| (f) Financial Assets | | | | |
| (i) Investments | 1,868.95 | 1,868.95 | 438.49 | 361.32 |
| (ii) Other Financial Assets | 2,281.28 | 585.13 | 3,121.36 | 809.23 |
| (g) Deferred Tax Assets (Net) | 909.28 | 411.65 | - | - |
| (h) Other Non-Current Assets | 1,226.05 | 1,091.79 | 1,239.10 | 1,112.89 |
| | 45,200.56 | 37,804.05 | 47,433.20 | 40,071.56 |
| CURRENT ASSETS | | | | |
| (a) Inventories | 8,193.88 | 8,945.29 | 12,572.96 | 11,844.73 |
| (b) Financial Assets | | | | |
| (i) Investments | - | - | - | 55.73 |
| (ii) Trade Receivables | 42,825.19 | 39,950.83 | 43,835.62 | 40,434.67 |
| (iii) Cash and Cash Equivalents | 682.80 | 1,387.45 | 2,379.39 | 2,314.01 |
| (iv) Bank balances other than (iii) above | 16,428.17 | 15,544.43 | 18,951.32 | 19,247.52 |
| (v) Loans | 3,698.91 | 3,602.99 | 4.03 | 6.91 |
| (vi) Other Financial Assets | 1,936.29 | 2,009.11 | 890.48 | 1,093.76 |
| (c) Current Tax Assets (Net) | 239.45 | 244.60 | 312.35 | 291.48 |
| (d) Other Current Assets (Refer Note 10) | 2,764.32 | 5,538.67 | 2,987.30 | 5,798.48 |
| | 76,769.01 | 77,223.37 | 81,933.45 | 81,087.29 |
| Asset Classified as Held for Sale | - | - | 717.24 | - |
| TOTAL ASSETS | 1,21,969.57 | 1,15,027.42 | 1,30,083.89 | 1,21,158.85 |
| EQUITY AND LIABILITIES | | | | |
| EQUITY | | | | |
| (a) Equity Share Capital | 1,053.70 | 1,046.91 | 1,053.70 | 1,046.91 |
| (b) Other Equity | 1,04,809.61 | 97,797.47 | 1,03,983.86 | 95,672.42 |
| (c) Non-Controlling Interest | - | - | 4,147.09 | 3,579.00 |
| LIABILITIES | | | | |
| NON-CURRENT LIABILITIES | | | | |
| (a) Financial Liabilities | | | | |
| (i) Borrowings | 1,967.29 | 3,509.53 | 1,984.57 | 3,559.22 |
| (ia) Lease Liabilities | 1,247.14 | 923.74 | 1,271.92 | 927.87 |
| (b) Provisions | 436.39 | 260.47 | 436.39 | 267.44 |
| (c) Deferred Tax Liabilities (Net) | - | - | 29.95 | 359.32 |
| (d) Other non-current liabilities | - | - | 4.71 | 6.06 |
| | 3,650.82 | 4,693.74 | 3,727.54 | 5,119.91 |
| CURRENT LIABILITIES | | | | |
| (a) Financial Liabilities | | | | |
| (i) Borrowings | 3,133.60 | 3,053.63 | 5,112.91 | 5,221.45 |
| (ia) Lease Liabilities | 423.99 | 263.48 | 440.99 | 275.47 |
| (ii) Trade Payables | | | | |
| (A) Total Outstanding Dues of Micro Enterprises and Small Enterprises | 645.14 | 833.91 | 896.02 | 1,103.65 |
| (B) Total Outstanding Dues of Creditors other than Micro Enterprises and Small Enterprises | 5,386.43 | 4,612.69 | 6,245.82 | 4,992.88 |
| (iii) Other Financial Liabilities | 2,262.74 | 1,975.83 | 3,063.99 | 2,993.70 |
| (b) Other Current Liabilities | 554.30 | 696.05 | 970.22 | 966.86 |
| (c) Provisions | 49.24 | - | 64.40 | - |
| (d) Current Tax Liabilities (Net) | - | 53.71 | 377.35 | 186.60 |
| | 12,455.44 | 11,489.30 | 17,171.70 | 15,740.61 |
| TOTAL EQUITY & LIABILITIES | 1,21,969.57 | 1,15,027.42 | 1,30,083.89 | 1,21,158.85 |



BLISS GVS PHARMA LIMITED
Regd. Office - 102, Hyde Park, Sakinaka Road, Andheri East- Mumbai-400072
CIN - L24230MH1984PLC034771

Statement of Cash Flow for the Year ended March 31, 2025

(₹ in Lakh)

| Particulars | Standalone | | Consolidated | |
|--|----------------|----------------|----------------|----------------|
| | Year Ended | | Year Ended | |
| | March 31, 2025 | March 31, 2024 | March 31, 2025 | March 31, 2024 |
| | Audited | Audited | Audited | Audited |
| A. CASH FLOW FROM OPERATING ACTIVITIES | | | | |
| Net Profit before Taxation and Exceptional Items | 9,417.11 | 11,134.38 | 12,563.92 | 14,606.81 |
| Adjustments for: | | | | |
| Depreciation and Amortisation expense | 2,704.72 | 2,351.93 | 2,941.76 | 2,637.98 |
| Finance costs | 658.38 | 580.61 | 812.00 | 691.21 |
| Interest income | (1,378.04) | (1,337.94) | (1,499.68) | (1,179.04) |
| Interest income on Income Tax refund | (15.18) | - | (15.18) | - |
| Dividend income | (12.60) | (12.60) | - | - |
| Rent received | (1.99) | (1.94) | (1.99) | (1.94) |
| Net Gain on sale of Current Investments carried at Fair Value through Profit or Loss | (11.23) | - | (19.34) | - |
| Gain/ Loss on fair value of investment | - | - | (29.78) | - |
| Provision for Employee Benefits | 323.40 | 104.39 | 332.58 | 111.46 |
| (Profit)/Loss on sale/scrapped/written off of Property, Plant and Equipment (net) | 31.94 | (33.78) | 49.20 | (28.59) |
| (Gain)/Loss on Foreign Exchange Fluctuations (net) | (130.17) | 340.03 | (532.63) | (2,265.43) |
| Bad Debts written off | - | 1,051.42 | - | 1,051.42 |
| Allowance and Provision for Doubtful Debts | 833.90 | 81.37 | 1,240.88 | 1,475.95 |
| Balance written off/back and other non cash item/exceptional items | 2,226.70 | 919.88 | 3,144.75 | 942.48 |
| Share Based Payment expenses | 414.00 | 381.57 | 414.00 | 381.57 |
| | 5,643.83 | 4,424.94 | 6,836.57 | 3,817.07 |
| Operating Profit before Working Capital changes | 15,060.94 | 15,559.32 | 19,400.49 | 18,423.88 |
| Movements in Working Capital: | | | | |
| Trade Receivables | (3,684.84) | (1,683.88) | (4,465.44) | (4,451.87) |
| Inventories | (646.91) | (2,233.85) | (3,045.42) | (2,242.18) |
| Loans and Other Financial Assets | (40.96) | (292.12) | (65.38) | (212.79) |
| Other Assets | 1,694.55 | 1,039.74 | 1,871.70 | 3,344.86 |
| Trade Payables | 623.47 | (2,108.43) | 1,083.80 | (2,510.03) |
| Other Financial Liabilities | 61.25 | 716.45 | (166.55) | 1,261.12 |
| Other Liabilities and Provisions | (314.44) | 153.83 | (358.32) | 153.79 |
| | (2,307.88) | (4,408.26) | (5,145.61) | (4,657.10) |
| Cash generated from Operations | 12,753.06 | 11,151.06 | 14,254.88 | 13,766.78 |
| Income taxes paid/refund (net) | (3,032.52) | (2,934.07) | (3,663.59) | (3,485.12) |
| Net Cash generated from Operating Activities | 9,720.54 | 8,216.99 | 10,591.29 | 10,281.66 |
| B. CASH FLOW FROM INVESTING ACTIVITIES | | | | |
| Payment to acquire Property, Plant and Equipment and CWIP | (6,850.34) | (3,867.68) | (7,606.53) | (2,832.93) |
| Payments for acquisition of intangible assets | (22.07) | - | (22.07) | - |
| Proceeds from sale of Property, Plant and Equipment | 177.20 | 25.38 | 341.21 | 60.33 |
| Increase/ (Decrease) in Other Bank Balances | (883.74) | (8,948.65) | 297.47 | (11,444.52) |
| Increase/(Decrease) in Fixed Deposits having maturity more than 12 months | (1,615.25) | 4,373.32 | (2,227.48) | 4,961.26 |
| Interest received | 1,395.87 | 585.78 | 1,643.64 | 500.84 |
| Dividend received | 12.60 | 12.60 | - | - |
| Rent received | 1.99 | 1.94 | 1.99 | 1.94 |
| Loan repaid by Subsidiaries | - | 1,233.50 | - | - |
| Purchase of Investments | (3,586.00) | - | (3,627.99) | (76.50) |
| Proceeds from Sale of Investments | 3,597.23 | - | 3,655.67 | 510.60 |
| Net Cash generated from/ (used in) Investing Activities | (7,772.51) | (6,583.81) | (7,544.09) | (8,318.98) |
| C. CASH FLOW FROM FINANCING ACTIVITIES | | | | |
| Proceeds from Secured Borrowings | 5,004.36 | 1,448.84 | 5,527.31 | 1,548.84 |
| Repayment of Secured Borrowings (net) | (6,467.03) | (2,457.05) | (7,174.67) | (2,438.42) |
| Payment of Lease Liabilities | (428.45) | (264.89) | (448.75) | (285.17) |
| Finance cost paid | (528.65) | (503.67) | (682.10) | (610.01) |
| Dividend paid | (539.48) | (534.09) | (544.87) | (539.49) |
| Proceeds from issue of Shares including Securities Premium | 288.62 | 231.40 | 288.62 | 231.40 |
| Share Application money received | - | 3.55 | - | 3.55 |
| Net Cash (used in)/ generated by Financing Activities | (2,670.63) | (2,075.91) | (3,034.46) | (2,089.30) |
| Net increase in Cash and Cash Equivalents (A+B+C) | (722.60) | (442.73) | 12.74 | (126.62) |
| Cash and Cash Equivalents at the beginning of the year | 1,417.46 | 1,860.19 | 2,359.06 | 2,500.69 |
| Effect of Exchange on restatement of Foreign Currency | - | - | 9.87 | (15.01) |
| Cash and Cash Equivalents at the end of year* | 694.86 | 1,417.46 | 2,381.67 | 2,359.06 |
| Components of Cash and Cash Equivalents | | | | |
| Balances with Banks | | | | |
| In Current accounts | 666.06 | 1,371.14 | 1,043.24 | 1,745.55 |
| In Deposit accounts | 14.79 | 14.15 | 1,326.06 | 561.82 |
| Cash on hand | 1.95 | 2.16 | 10.09 | 6.64 |
| Gratuity Trust Bank Account (Included under Current Financial Assets - Others) | 2.28 | 45.05 | 2.28 | 45.05 |
| Unrealised exchange loss/ (gain) on Cash and Cash Equivalents | 9.78 | (15.04) | 9.87 | (15.01) |
| Cash and Cash Equivalents as per Statement of Cash Flows | 694.86 | 1,417.46 | 2,391.54 | 2,344.05 |

Notes:

The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS 7) - "Statement of Cash Flows".



Notes :

- 1 The above audited financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 12, 2025. These audited financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 2 The above audited financial results for the quarter and year ended March 31, 2025 are prepared in compliance with Ind AS, which have been audited by the statutory auditors of the Company. The statutory auditors have issued audit reports with unmodified opinion on the audited standalone and consolidated financial results.
- 3 As the Company's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment information is disclosed.
- 4 Employee Benefit Expenses includes Share Based Payment expense on account of ESOP Scheme, 2019 of ₹ 414.00 Lakh (Year ended March 31, 2024 ₹ 381.57 Lakh) as per Ind AS 102 "Share based Payment" for the year ended March 31, 2025.
- 5 During the year ended March 31, 2025, the Company has allotted 6,79,450 equity shares of ₹ 1 each fully paid, on exercise of stock options by employees in accordance with the Company's ESOP Scheme, 2019. From the total 59,74,000 number of options granted, the outstanding number of options as at March 31, 2025 are 13,83,750.
- 6 The Board of Directors has recommended final dividend of Re. 0.50 paise per share. The payment is subject to approval of shareholders in the ensuing Annual General Meeting of the Company.
- 7 The Consolidated Financial Results includes the Results of the following entities:

| Name of the Company | % of Shareholding | Consolidated as |
|-----------------------------------|-------------------|----------------------|
| Kremoint Pharma Pvt. Ltd. | 70% | Subsidiary |
| Asterisk Lifesciences Ltd. | 100% | Subsidiary |
| Bliss GVS International Pte. Ltd. | 100% | Subsidiary |
| Eipii Exports Pvt. Ltd. | 70% | Step-Down Subsidiary |
| Greenlife Bliss Healthcare Ltd. | 51% | Step-Down Subsidiary |
| Asterisk Lifesciences (GH) Ltd. | 100% | Step-Down Subsidiary |

- 8 The Board of Directors in its meeting held on May 12, 2025 has approved the sale of 51% stake in its step-down subsidiary Greenlife Bliss Healthcare Ltd, Nigeria held by its Subsidiary Bliss GVS International Pte Ltd, Singapore to non-controlling shareholder for a total consideration of USD 13,00,000 subject to necessary regulatory and other approvals. The transaction is expected to be completed in H1 FY 2025-26.
- 9 The Board of Directors in its meeting held on May 12, 2025 has approved the issuance of 12,10,000 equity shares as Sweat equity shares for non-cash consideration having the face value of Re. 1 each to Mr. Gagan Harsh Sharma - Managing Director and Mr. Vishal Rao - Vice President of the Company having Fair Market Value/Volume Weighted Average Price of ₹ 148.72 per share. These shares were allotted in compliance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and subject to shareholder's approval.
- 10 The Company has classified Assets located at Ambarnath, Maharashtra comprising of Land and Building as held for sale as on March 31, 2025 consequent to the MOU entered by its Subsidiary Company Kremoint Pharma Pvt Ltd, India. The transaction is expected to be completed by September 30, 2025.
- 11 The Company has invested in, given loans, accrued interest and due thereon and trade receivables from one of its subsidiary and its step-down subsidiaries aggregating to ₹ 15,255.83 Lakh. This subsidiary had a consolidated negative net worth. In view of macro-economics business scenarios, during the previous year the management has assessed these investments and loans for impairment and based thereon, investments in/ loan given to Company's subsidiary Bliss GVS International Pte Ltd including step-down subsidiaries viz Greenlife Bliss Healthcare Ltd, Asterisk Lifesciences DRC and Asterisk Lifesciences (GH) Ltd had been impaired and accordingly an amount of ₹ 4,108.61 Lakh and ₹ 2,919.61 Lakh in standalone and consolidated financial results/statements respectively had been recognised as an exceptional item for the quarter and year ended March 31, 2024 respectively.
- 12 The figures for the quarter ended March 31 are the balancing figures between audited figures in respect of the year ended March 31 and the published year to date unaudited figures for the nine months ended ended December 31 of the respective financial year.

Place : Mumbai
Date : May 12, 2025



For BLISS GVS PHARMA LIMITED


Gagan Harsh Sharma
Managing Director
Din : 07939421

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REPORT TO THE BOARD OF DIRECTORS OF BLISS GVS PHARMA LIMITED

Report on the Audit of the Standalone Financial Results

Opinion

We have audited the accompanying annual Standalone Financial Results of **BLISS GVS PHARMA LIMITED** ("the Company") for the year ended March 31, 2025, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations"), duly initialled by us for identification.

In our opinion and to the best of our information and according to the explanations given to us, these Standalone Financial Results:

- i) are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- ii) give a true and fair view in conformity with the recognition and measurement principles of applicable Indian Accounting Standards (Ind AS), and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Standalone Financial Results

These Standalone Financial Results have been prepared on the basis of the annual standalone financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these Standalone Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275



In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter


The Standalone Financial Results include the results for the quarter ended March 31, of the respective financial years, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the end of the third quarter of the relevant financial year, which were subjected to limited review by us.

Our opinion on these Standalone Financial Results is not modified in respect of the above matter.

For KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

Firm Regn. No.: 104607W / W100166



Janshed K. Udawadia

PARTNER

M. No.: 124658

UDIN: 25124658BMJKB3227

Mumbai: May 12, 2025.



KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REPORT TO THE BOARD OF DIRECTORS OF BLISS GVS PHARMA LIMITED

Report on the Audit of the Consolidated Financial Results

Opinion

We have audited the accompanying annual Consolidated Financial Results of **BLISS GVS PHARMA LIMITED** (hereinafter referred to as the "the Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as the "Group"), for the year ended March 31, 2025, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India ("the SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations"), duly initialled by us for identification.

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements of the subsidiaries, the aforesaid, Consolidated Financial Results:

- i) include the financial results of the following entities:
 - A. **Incorporated in India:**
 - 1. Kremoint Pharma Private Limited, India
 - 1.1 Eipii Exports Private Limited, India (Subsidiary of 1. above)
 - B. **Incorporated outside India:**
 - 2. Bliss GVS International Pte. Ltd., Singapore
 - 2.1 Greenlife Bliss Healthcare Ltd, Nigeria (Subsidiary of 2. above)
 - 2.2 Asterisk Lifesciences (GH) Limited, Ghana (Subsidiary of 2. above)
 - 3. Asterisk Lifesciences Limited (UK), United Kingdom
- ii) are presented in accordance with the requirements of Regulation 33 of the LODR Regulations, in this regard; and
- iii) give a true and fair view in conformity with the recognition and measurement principles of the applicable Indian Accounting Standards (Ind AS), and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Group for the year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275

Board of Directors' Responsibilities for the Consolidated Financial Results

These Consolidated Financial Results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these Consolidated Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. The respective Board of Directors of the companies included in the Group, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group, and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated Financial Results by the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intend to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results of the entities within the Group to express an opinion on the consolidated financial results. We are responsible for the direction, supervision and performance of the audit of financial results of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the Consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations, as amended, to the extent applicable.

Other Matters

- a) We did not audit the financial statements of six subsidiaries / step down subsidiaries included in the consolidated financial results, whose financial results (before consolidated adjustments) reflect the Group's share of the following items for the quarter and year ended March 31, 2025:

| (Rs. in Lakh) | | | |
|---------------|----------------------------|------------------------------|---------------------------|
| Sr. No | Particulars | Quarter ended March 31, 2025 | Year ended March 31, 2025 |
| 1 | Total Assets | 25,854.40 | 25,854.40 |
| 2 | Total Revenue | 5,298.57 | 21,902.45 |
| 3 | Profit / (Loss) after Tax | 399.68 | 2,093.08 |
| 4 | Total Comprehensive Income | 379.75 | 1,951.16 |
| 5 | Net Cash inflows | - | 770.03 |

These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries / step down subsidiaries, is



**KALYANIWALLA
& MISTRY LLP**

based solely on the reports of other auditors and the procedures performed by us are as stated in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results paragraph above.


Our opinion on these Consolidated Financial Results is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.

- b) The Consolidated Financial Results include the results for the quarter ended March 31, of the respective financial years, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the end of the third quarter of the relevant financial year, which were subjected to limited review by us.

Our opinion on these Consolidated Financial Results is not modified in respect of the above matter.

**For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS**

Firm Registration No. 104607W/W100166



Jamshed K. Udwadia
PARTNER

M. No.: 124658

UDIN: 25124658BMJKBUI625

Mumbai, May 12, 2025.



May 12, 2025

| | |
|--|--|
| To The Manager, Listing Department National Stock Exchange of India Ltd. Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: BLISSGVS | To The General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 506197 |
|--|--|

Subject: Declaration pursuant to Regulation 33(3)(d) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the annual audited financial results (Standalone and Consolidated) for the year ended March 31, 2025

Dear Sir/Madam,

We, Bliss GVS Pharma Limited, hereby declare that the statutory auditor has issued an audit report with and Unmodified Opinion on Standalone and Consolidated audited financial results of the Company for the year ended March 31, 2025.

Kindly take the same on your record.

Thanking you.

Yours Faithfully,

For **Bliss GVS Pharma Limited**

Deepak Sawant
Chief Financial Officer

- A. **FINANCIAL RESULTS** – Refer Annexure-1
- B. **STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC:** Not Applicable
- C. **FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES:** Not Applicable
- D. **FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS:** Will be filed along with XBRL for Financial Result.
- E. **STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG WITH ANNUAL AUDITED FINANCIAL RESULTS:** Not Applicable.

Brief Profile of the Internal Auditor of the Company

ABOUT BDO



BDO GLOBAL

- BDO's foundation was done in the year 1963, the initial international organisation was known as the Binder Seidman International Group, formed by respected firms.
- In 1973 the organisation adopted the name BDO, made up from the initials of the three founding European firms: Binder (UK), Dijkster (Netherlands) and Otte (Germany).
- In the subsequent **50+ years**, BDO has grown into a **US\$15 billion+** business, extending in across **166 countries** and territories, with **119,611 people** working out of **1,800 offices** – and they're all working towards one goal: to provide our clients with exceptional service.

Our Global CEO

- Mr. Keith Farlinger
Our Awards are

- IAB Network of the Year
- BDO South Africa: Best Tax Firm of the Year, 2015
- BDO Australia: Best Provider-Client Choice Awards
- BDO Global Outsourcing: International Payroll Award
- BDO Sweden: BDO Ranked 1st for client Satisfaction
- BDO UK: Ranked Market Leader for client satisfaction

BDO INDIA LLP

- BDO India LLP is the India member firm of BDO International.
- BDO India offers strategic, operational, accounting and tax & regulatory advisory & assistance for both domestic and international organisations across a range of industries. We are led by **more than 350 Partners & Directors** with a team of **over 11,000 professionals** operating across **14 cities**.

Our Key People are

- Mr. Milind Kothari, Managing Partner, BDO India LLP

Auditors' Appointed & Date of Appointment:

- Mr. Hiren Upadhyay, Partner & Leader West, Business Advisory Services on May 12, 2025 for FY 2025-2026

Reason for change: Re-Appointment

Brief Profile of Secretarial Auditor

| | |
|----------------------------|---|
| Name of the Firm | AVS & Associates, Practicing Company Secretaries |
| Area of Services | <ul style="list-style-type: none">• Company Law Matters such as Company and LLP Formation, Conversion of Company into LLP & Vice Versa, Merger & Amalgamation of Companies, Secretarial Audits for Public / Listed Companies, Compounding of Offences, Condonation of Delays with ROC/RD/NCLT & Execution on Resolution Plan under Insolvency and Bankruptcy Code etc.• Securities Laws Matters such as Periodical Compliances of Listed Companies (Equity / Debt), Corporate Governance Report, Revocation of Suspension of Trading of Shares, Delisting of Equity Shares, Reclassification of Shareholders of Listed Company, Preferential Issue & Private Placement, Issue of Share Warrants, ESOP etc.• Foreign Exchange Management Act (FEMA) Matters such as Consultancy relating to FDI / ODI, FCGPR, Annual Return of Foreign Assets & Liabilities, Liaisoning with RBI / AD Banks etc.• Other Matters: Drafting and Vetting of Various Deeds / Agreements / Documents as per Company Law Compliances and any other laws applicable, MSME Registration, etc. |
| Date of Appointment | 12-05-2025 |
| Reason for change | Appointment |
| Term of Appointment | F.Y. 2025-2026 to F.Y. 2029-2030 (5 Years) |

'Annexure - 6'

(Pursuant to SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023)

| No. | Particulars | Details |
|-----|---|--|
| 1. | The amount and percentage of the turnover or revenue or income and net worth contributed by such unit / division / undertaking subsidiary/ associate company of the listed entity during the last financial year. | Turnover: 1,260.77 Lakh Net worth: 994.01 Lakh (As on March 31, 2025) |
| 2. | Date on which the agreement for sale has been entered into | To be entered on or before September 30, 2025 |
| 3. | The expected date of completion of sale / disposal | Subject to requisite approvals and procedures in Singapore and Nigeria, the proposed restructuring is expected to be completed on or before September 30, 2025. |
| 4. | Consideration received from such sale/ disposal | Greenlife Pharmaceuticals Limited (Nigeria) will acquire the entire shares held by Bliss GVS International Pte. Ltd. (Singapore) in Greenlife Bliss Healthcare Ltd (Nigeria) at a Consideration price of USD 13,00,000 on an arm's length basis for consideration. |
| 5. | Brief details of buyers and whether any of the buyers belong to the promoter / promoter group/ group companies. If yes, details thereof | Name of the Buyer - Greenlife Pharmaceuticals Limited (Nigeria) The existing non-controlling shareholder of Greenlife Bliss Healthcare Ltd (Nigeria), holding 49% stake as of March 31, 2025. No, the buyer does not belong to Group Companies. |
| 6. | Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms' length" | The proposed transaction falls within the purview of related party transactions and shall be done on an arm's length basis. |

| | | |
|----|---|----------------|
| 7. | whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations | Not Applicable |
| 8. | In case of a slump sale, indicative disclosures provided for amalgamation / merger, shall be disclosed by the listed entity with respect to such slump sale | Not Applicable |

(Pursuant to SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023)

| No. | Particulars | Details |
|-----|---|--|
| 1 | Type of securities proposed to be issued | Equity Shares |
| 2 | Type of Issuance | Sweat Equity Shares |
| 3 | Total Number of Securities proposed to be issued the total amount for which the securities will be issued (approximately) | Up to 12,10,000 (Twelve Lakhs Ten Thousand) Equity Shares having a face value of Re.1/- (Rupees One Only) for non-cash consideration as Sweat Equity Shares. |

Details of Allotment

| No. | Name of the Proposed Allottee(s) | No. of Equity Shares to be Allotted | Category of Allottee (s) | Issue Price / Allotment Price |
|-----|---|-------------------------------------|-------------------------------|--|
| 1 | Gagan Harsh Sharma (Managing Director) | 8,50,000 | Promoter Promoter Group | Non-cash consideration is being proposed in recognition of the value additions made by Mr. Gagan Harsh Sharma and Mr. Vishal Vijay Rao as well as their continued contributions during their ongoing association with the Company. |
| 2 | Vishal Vijay Rao (Vice President) | 3,60,000 | | |
| | Total | 12,10,000 | | |